TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Effectiveness Trial Examining the Addition of Zinc to the Current Case Management Package of Diarrhea in a Primary Health Care Setting.
Brief Summary: Several studies have shown the beneficial effect of zinc treatment in acute diarrhea. There was a significant reduction in duration of the treated episodes and in their severity as measured by diarrheal stool output or frequency. Zinc is a potentially important immunomodulator or nutraceutical which may have great impact as therapeutic agent in conditions like diarrhea and pneumonia. The issue is whether and how zinc should be introduced in primary health care programs for treatment of acute diarrhea. A practical, sustainable intervention for introduction of zinc as treatment of acute diarrhoea in national programs is therefore required. This study aimed to address this issue.


Options:
A: Intervention Type: DRUG; Name: Zinc; Assigned to Arm(s): N/A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Zinc and ORS | Arm Label: 2; Type: OTHER; Interventions: Drug: ORS only | Intervention Type: DRUG; Name: Zinc and ORS; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: ORS only; Assigned to Arm(s): 2
C: Intervention Type: DRUG; Name: Vitamin + Zinc + micronutrient mixture; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Vitamin A + Zinc; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: Zinc sulphate; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: "A Randomized, Double-Blind, Placebo-Controlled Study of Divalproex Extended Release Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to- Severe Hypomania or Mild Mania"
Brief Summary: The purpose of this research study is to evaluate the safety, tolerability, and efficacy of divalproex extended release compared to placebo (sugar pill without medication) in the treatment of bipolar disorder with moderate to severe hypomania or mild mania. Divalproex extended release is approved by the United States Food and Drug Administration (FDA) for the treatment of epilepsy and for prevention of migraine headaches.


Options:
A: Intervention Type: DRUG; Name: Divalproex Sodium Extended-Release Tablets; Assigned to Arm(s): N/A
B: Arm Label: lithium plus carbamazepine; Type: EXPERIMENTAL; Interventions: Drug: lithium plus carbamazepine | Arm Label: lithium plus valproate; Type: ACTIVE_COMPARATOR; Interventions: Drug: lithium plus valproate | Intervention Type: DRUG; Name: lithium plus carbamazepine; Assigned to Arm(s): lithium plus carbamazepine | Intervention Type: DRUG; Name: lithium plus valproate; Assigned to Arm(s): lithium plus valproate
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Divalproex | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: Divalproex; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Divalproex Sodium (Depakote ER); Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus
Brief Summary: The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.


Options:
A: Arm Label: Metformin alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: Glargine followed by Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Glargine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Liraglutide + Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin, Drug: Liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Glargine followed by Metformin, Liraglutide + Metformin, Metformin alone | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): Liraglutide + Metformin | Intervention Type: DRUG; Name: Glargine; Assigned to Arm(s): Glargine followed by Metformin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glipizide | Arm Label: glipizide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Glipizide; Assigned to Arm(s): metformin | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): glipizide
D: Arm Label: liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: Metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): liraglutide | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Metformin

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus
Brief Summary: The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.


Options:
A: Arm Label: Liraglutide; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Exenatide; Type: ACTIVE_COMPARATOR; Interventions: Drug: exenatide | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide | Intervention Type: DRUG; Name: exenatide; Assigned to Arm(s): Exenatide
B: Arm Label: linagliptin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: linagliptin | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin 5 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
C: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
D: Arm Label: linagliptin; Type: EXPERIMENTAL; Interventions: Drug: linagliptin, Drug: glimepiride placebo | Arm Label: glimepiride 1-4 mg QD; Type: ACTIVE_COMPARATOR; Interventions: Drug: glimepiride, Drug: linagliptin placebo | Intervention Type: DRUG; Name: linagliptin; Assigned to Arm(s): linagliptin | Intervention Type: DRUG; Name: glimepiride; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: linagliptin placebo; Assigned to Arm(s): glimepiride 1-4 mg QD | Intervention Type: DRUG; Name: glimepiride placebo; Assigned to Arm(s): linagliptin

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients With Drug-Naive, Recently Diagnosed Type 2 Diabetes Mellitus
Brief Summary: The study will compare and evaluate the effects of long-term treatment of monotherapy with rosiglitazone, metformin and glyburide/glibenclamide on the improvement and maintenance of glycemic control in patients with recently diagnosed type 2 diabetes mellitus.


Options:
A: Arm Label: BI 1356; Type: ACTIVE_COMPARATOR; Interventions: Drug: BI 1356 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: BI 1356; Assigned to Arm(s): BI 1356 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Rosiglitazone; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: glyburide; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: metformin; Assigned to Arm(s): N/A
C: Arm Label: Glimepiride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Glimepiride, Drug: Metformin | Arm Label: Canagliflozin 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Arm Label: Canagliflozin 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Canagliflozin (JNJ-28431754), Drug: Metformin | Intervention Type: DRUG; Name: Glimepiride; Assigned to Arm(s): Glimepiride | Intervention Type: DRUG; Name: Canagliflozin (JNJ-28431754); Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): Canagliflozin 100 mg, Canagliflozin 300 mg, Glimepiride
D: Arm Label: T2D, Dialysis, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Dialysis, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Liraglutide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Liraglutide | Arm Label: T2D, Normal kidney function, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Liraglutide | Intervention Type: DRUG; Name: Liraglutide; Assigned to Arm(s): T2D, Dialysis, Liraglutide, T2D, Dialysis, Placebo, T2D, Normal kidney function, Liraglutide, T2D, Normal kidney function, Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reinfusion of Enriched Progenitor Cells And Infarct Remodeling in Acute Myocardial Infarction (REPAIR - AMI)
Brief Summary: Impaired contractile function after a heart attack of the heart is a major cause of "heart failure" limiting quality of life and prognosis, which cannot be prevented even with optimal standard therapy, including immediate balloon/stent dilation of the infarct vessel.

The aim of the REPAIR-AMI trial is to investigate whether infusion of progenitor cells into the infarct vessel (after successful reperfusion therapy) may improve left ventricular contractile function compared to placebo therapy. After bone marrow aspiration progenitor cells are enriched via a centrifugation method.


Options:
A: Arm Label: BMC; Type: EXPERIMENTAL; Interventions: Biological: Intracoronary infusion of enriched bone marrow-derived progenitor cells | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo medium supplemented with autologous serum | Intervention Type: BIOLOGICAL; Name: Intracoronary infusion of enriched bone marrow-derived progenitor cells; Assigned to Arm(s): BMC | Intervention Type: BIOLOGICAL; Name: Placebo medium supplemented with autologous serum; Assigned to Arm(s): Placebo
B: Arm Label: Cell therapy; Type: EXPERIMENTAL; Interventions: Drug: Autologous, Unfractionated Bone Marrow Mononuclear Cells | Intervention Type: DRUG; Name: Autologous, Unfractionated Bone Marrow Mononuclear Cells; Assigned to Arm(s): Cell therapy
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: autologous stem cells | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo suspension | Intervention Type: OTHER; Name: autologous stem cells; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: placebo suspension; Assigned to Arm(s): 2
D: Intervention Type: PROCEDURE; Name: cd133+cell intracoronary administration; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Rituximab on the Progression of Type 1 Diabetes in New Onset Subjects
Brief Summary: Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the insulin-producing beta cells in the pancreas. Without these beta cells, the body cannot maintain proper blood glucose levels in response to daily activities such as eating or exercise. With fewer insulin producing cells blood glucose increases, causing hunger, thirst, and unexplained weight loss. By the time these symptoms develop, 80-90% of a person's beta cells have already been destroyed. However, this also means that between 10-20% of these cells remain that continue to produce insulin.

Scientists have learned that two types of immune cells, B cells and T cells, are involved in causing type 1 diabetes. T cells are responsible for attacking and destroying the beta cells that make insulin. Although they don't attack insulin producing cells, B cells may be what trigger the T cells to attack.

This study will investigate the use of rituximab to see if it can help lower the number of immune B cells thereby preventing the destruction of any remaining insulin producing beta cells that remain at diagnosis. Rituximab is approved by the Food and Drug Administration (FDA) for the treatment of a condition called B-lymphocyte lymphoma. Its effects on the immune system are well understood through its use in organ transplantation. Research has shown that rituximab might be helpful in treating other conditions caused by T cells and B cells, including type 1 diabetes. The goal of this study is to find out if rituximab can preserve residual insulin secretion and prevent further beta cell destruction in type 1 diabetes.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: rituximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): 1
B: Arm Label: Arm A: CHOP-21; Type: ACTIVE_COMPARATOR; Interventions: Drug: CHOP regimen | Arm Label: Arm B: CHOP-21 + Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: rituximab, Drug: CHOP regimen | Intervention Type: BIOLOGICAL; Name: rituximab; Assigned to Arm(s): Arm B: CHOP-21 + Rituximab | Intervention Type: DRUG; Name: CHOP regimen; Assigned to Arm(s): Arm A: CHOP-21, Arm B: CHOP-21 + Rituximab
C: Arm Label: Rituximab Intravenous Infusion; Type: EXPERIMENTAL; Interventions: Drug: Anti-CD20 (rituximab) | Arm Label: Placebo Intravenous Infusion; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo Comparator | Intervention Type: DRUG; Name: Anti-CD20 (rituximab); Assigned to Arm(s): Rituximab Intravenous Infusion | Intervention Type: DRUG; Name: Placebo Comparator; Assigned to Arm(s): Placebo Intravenous Infusion
D: Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis
Brief Summary: The purpose of this study is to compare the efficacy of visilizumab to placebo in subjects with intravenous steroid-refractory ulcerative colitis.


Options:
A: Arm Label: Abatacept (ABA); Type: EXPERIMENTAL; Interventions: Drug: abatacept (ABA) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: abatacept; Type: OTHER; Interventions: Drug: abatacept | Intervention Type: DRUG; Name: abatacept (ABA); Assigned to Arm(s): Abatacept (ABA) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: abatacept; Assigned to Arm(s): abatacept
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: visilizumab | Arm Label: visilizumab; Type: EXPERIMENTAL; Interventions: Drug: visilizumab | Intervention Type: DRUG; Name: visilizumab; Assigned to Arm(s): visilizumab | Intervention Type: DRUG; Name: visilizumab; Assigned to Arm(s): placebo
C: Arm Label: AVX 470; Type: ACTIVE_COMPARATOR; Interventions: Drug: AVX 470 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: AVX 470; Assigned to Arm(s): AVX 470 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prevention of Suicide in Primary Care Elderly: Collaborative Trial
Brief Summary: The purpose of this study was to determine the effect of a primary care intervention on reducing suicidal ideation and depression in older patients.


Options:
A: Intervention Type: DRUG; Name: Treatment of depression; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Suicide prevention intervention; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Suicide prevention treatment; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: treatment guidelines and depression care management; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Collaborative depression care management | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced usual care | Intervention Type: BEHAVIORAL; Name: Collaborative depression care management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Enhanced usual care; Assigned to Arm(s): 2
D: Arm Label: PND-MCI; Type: EXPERIMENTAL; Interventions: Other: multi-component intervention | Arm Label: usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Intervention Type: OTHER; Name: multi-component intervention; Assigned to Arm(s): PND-MCI | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): usual care

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Selenium and Immune Function
Brief Summary: The aim of the study is to investigate the relationship between dose and form of selenium on immune function, and to identify functional markers of selenium status.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: 50ug selenium enriched yeast; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 50ug selenium enriched yeast | Arm Label: 100ug selenium enriched yeast; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 100ug selenium enriched yeast | Arm Label: 200ug selenium enriched yeast; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 200ug selenium enriched yeast | Arm Label: Control onion; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Control onion | Arm Label: Enriched onion; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Enriched onion | Intervention Type: DIETARY_SUPPLEMENT; Name: 50ug selenium enriched yeast; Assigned to Arm(s): 50ug selenium enriched yeast | Intervention Type: DIETARY_SUPPLEMENT; Name: 100ug selenium enriched yeast; Assigned to Arm(s): 100ug selenium enriched yeast | Intervention Type: DIETARY_SUPPLEMENT; Name: 200ug selenium enriched yeast; Assigned to Arm(s): 200ug selenium enriched yeast | Intervention Type: DIETARY_SUPPLEMENT; Name: Control onion; Assigned to Arm(s): Control onion | Intervention Type: DIETARY_SUPPLEMENT; Name: Enriched onion; Assigned to Arm(s): Enriched onion | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: AREDS participants; Type: N/A; Interventions: N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: vitamin and mineral supplement, Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Escherichia coli Endotoxin (LPS), Drug: 100% O2, Drug: nitroglycerin | Intervention Type: DRUG; Name: vitamin and mineral supplement; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Escherichia coli Endotoxin (LPS); Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: 100% O2; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: nitroglycerin; Assigned to Arm(s): 1, 2
D: Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin C; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin E; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: beta-carotene; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: folic acid/Vitamin B6/Vitamin B12; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cost Effectiveness and Efficacy of Kypho and Vertebro Plasty Trial
Brief Summary: Randomized trial comparing cost effectiveness and efficacy of kyphoplasty vs vertebroplasty for the treatment of painful, osteoporotic vertebral compression fractures.


Options:
A: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: percutaneous injection of cement into the vertebral body | Arm Label: Medical Treatment; Type: ACTIVE_COMPARATOR; Interventions: Other: Medical treatment | Intervention Type: PROCEDURE; Name: percutaneous injection of cement into the vertebral body; Assigned to Arm(s): vertebroplasty | Intervention Type: OTHER; Name: Medical treatment; Assigned to Arm(s): Medical Treatment
B: Arm Label: Vertebroplasty; Type: EXPERIMENTAL; Interventions: Device: Percutaneous vertebroplasty | Arm Label: Control Group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Sham vertebroplasty | Intervention Type: DEVICE; Name: Percutaneous vertebroplasty; Assigned to Arm(s): Vertebroplasty | Intervention Type: PROCEDURE; Name: Sham vertebroplasty; Assigned to Arm(s): Control Group
C: Arm Label: vertebroplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Arm Label: kyphoplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Kyphoplasty | Intervention Type: PROCEDURE; Name: Kyphoplasty; Assigned to Arm(s): kyphoplasty, vertebroplasty
D: Arm Label: vertebroplasty; Type: EXPERIMENTAL; Interventions: Procedure: percutaneous vertebroplasty | Arm Label: sham procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: sham procedure | Intervention Type: PROCEDURE; Name: percutaneous vertebroplasty; Assigned to Arm(s): vertebroplasty | Intervention Type: PROCEDURE; Name: sham procedure; Assigned to Arm(s): sham procedure

Answer: C